Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.

Abstract

TIP had major activity in this setting, with a 58% objective response rate, 17% complete response rate, durable complete responses (six of nine persisting), and relatively well-tolerated toxicity, with no toxic deaths. The activity of TIP, a novel taxol-cisplatin-based regimen, in recurrent or metastatic head and neck SCC should be confirmed in a phase III trial.

Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck

“…We are encouraged by the 1 year survival of 37% among patients with recurrent or metastatic disease, despite the small number of patients in this study, because historical data suggests that 1-year survival among these patients is about 20%. 15 Our results are comparable to those in a recent report from the M. D. Anderson Cancer Center by Shin et al 19 Paclitaxel was combined with ifosfamide and cisplatin in 53 patients with recurrent or metastatic SCCHNC. The response rate was 58% with a duration of response of 4.9 months, which were very similar to the results of our study.…”

Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck

“…13,15 Based on the single-agent activity of these drugs, the preferential toxicity profile, and a potentially higher therapeutic index than that of cisplatin, 5-FU, or methotrexate in patients with recurrent or metastatic SCCHN, we conducted a Phase II study combining paclitaxel, ifosfamide, and cisplatin (TIP) to treat these patients. 16 The regimen produced documented high overall response rates including prolonged duration of CR and encouraging median and 1 and 2-year median survival rates. 16 However, the TIP regimen induced significant degrees of peripheral neuropathy, fatigue, emesis, and anorexia, particularly when patients received more than four to six courses of treatment.…”

“…16 The regimen produced documented high overall response rates including prolonged duration of CR and encouraging median and 1 and 2-year median survival rates. 16 However, the TIP regimen induced significant degrees of peripheral neuropathy, fatigue, emesis, and anorexia, particularly when patients received more than four to six courses of treatment.…”

Update on role of chemotherapy in head and neck squamous cell cancer

“…59 Response rates in studies comparing triple-drug regimens such as cisplatin or carboplatin + ifosfamide + paclitaxel or cisplatin + 5-FU + docetaxel have been as high as 60%, even in pretreated patients, with median of survival of 9-11 months. 71 Another more complex regimen of cisplatin + methotrexate + bleomycin + vincristine compared with cisplatin + 5-FU or with cisplatin alone found similarly improved response rate and greater toxicity for combination regimens, but no survival advantage over single-agent therapy.…”